Articles
RSSOncology R&D Challenges & Opportunities
January 22, 2010
•Article: Oncology R&D Challenges & Opportunities
By Cliff Mintz Ph.D., Life Science Leader magazine
Millennium Pharmaceuticals, Inc. is one of only a handful of biotechnology companies that was built almost exclusively on a genomics and bioinformatics technology platform. Despite modest beginnings in 1993, the company has transformed itself from a fledgling genomics startup into a fully integrated biopharmaceutical company. Its flagship product is VELCADE (bortezomib) for Injection, an FDA-approved treatment for multiple myeloma and relapsed mantle cell lymphoma. In May 2008, the company was acquired by Takeda Pharmaceutical Company, Japan's largest pharmaceutical company, and currently operates as an independent subsidiary known as Millennium: The Takeda Oncology Company.
Used with permission from Life Science Leader magazine.
Click Here To Download:•Article: Oncology R&D Challenges & Opportunities
